Krzysztof Sztanke

Prof. Krzysztof Sztanke

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KSKrzysztof Sztanke
Krzysztof Sztanke
AMAgata Maziarka
Agata Maziarka
AOAnna Osinka
Anna Osinka
MSMałgorzata Sztanke
Małgorzata Sztanke

9 March 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
KDKatarzyna Dziąbowska-Grabias
Katarzyna Dziąbowska-Grabias
MSMałgorzata Sztanke
Małgorzata Sztanke
PZPrzemysław Zając
Przemysław Zając
MCMichał Celejewski
Michał Celejewski
KKKatarzyna Kurek
Katarzyna Kurek
KSKrzysztof Sztanke
Krzysztof Sztanke
Inflammatory bowel diseases (IBD) are a group of chronic, incurable diseases of the digestive tract, the etiology of which remains unclear to this day. IBD result in significant repercussions on the quality of patients’ life. There is a continuous increase in the incidence and prevalence of IBD worldwide, and it is becoming a significant public health burden. Pharmaceuticals commonly used in IBD management, for example, mesalamine, sulfasalazine, corticosteroids, and others, expose patients to diverse, potentially detrimental side effects and frequently do not provide sufficient disease control. The chronic inflammation underlies the etiology of IBD and closely associates with oxidative/nitrosative stress and a vast generation of reactive oxygen/nitrogen species. Relative to this, several substances with antioxidant and anti-inflammatory properties are now intensively researched as possible adjunctive or independent treatment options in IBD. Representatives of several different groups, including natural and chemical compounds will be characterized in this dissertation.

5 January 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MJMałgorzata Janicka
Małgorzata Janicka
MSMałgorzata Sztanke
Małgorzata Sztanke
KSKrzysztof Sztanke
Krzysztof Sztanke
Penetration through the blood-brain barrier (BBB) is desirable in the case of potential pharmaceuticals acting on the central nervous system (CNS), but is undesirable in the case of drug candidates acting on the peripheral nervous system because it may cause CNS side effects. Therefore, modeling of the permeability across the blood-brain barrier (i.e., the logarithm of the brain to blood concentration ratio, log BB) of potential pharmaceuticals should be performed as early as possible in the preclinical phase of drug development. Biomimetic chromatography with immobilized artificial membrane (IAM) and the quantitative structure-activity relationship (QSAR) methodology were successful in modeling the blood-brain barrier permeability of 126 drug candidates, whose experimentally-derived lipophilicity indices and computationally-derived molecular descriptors (such as molecular weight (MW), number of rotatable bonds (NRB), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), topological polar surface area (TPSA), and polarizability (α)) varied by class. The QSARs model established by multiple linear regression showed a positive effect of the lipophilicity (log kw, IAM) and molecular weight of the compound, and a negative effect of the number of hydrogen bond donors and acceptors, on the log BB values. The model has been cross-validated, and all statistics indicate that it is very good and has high predictive ability. The simplicity of the developed model, and its usefulness in screening studies of novel drug candidates that are able to cross the BBB by passive diffusion, are emphasized.

23 January 2020 in Molecules
Verified
Journal Article
Open access
PDF file
MJMałgorzata Janicka
Małgorzata Janicka
MSMałgorzata Sztanke
Małgorzata Sztanke
KSKrzysztof Sztanke
Krzysztof Sztanke
The permeation of the blood-brain barrier is a very important consideration for new drug candidate molecules. In this research, the reversed-phase liquid chromatography with different columns (Purosphere RP-18e, IAM.PC.DD2 and Cosmosil Cholester) was used to predict the penetration of the blood-brain barrier by 65 newly-synthesized drug-like compounds. The linear free energy relationships (LFERs) model (log BB = c + eE + sS + aA + bB + vV) was established for a training set of 23 congeneric biologically active azole compounds with known experimental log BB (BB = Cblood/Cbrain) values (R2 = 0.9039). The reliability and predictive potency of the model were confirmed by leave-one-out cross validation as well as leave-50%-out cross validation. Multiple linear regression (MLR) was used to develop the quantitative structure-activity relationships (QSARs) to predict the log BB values of compounds that were tested, taking into account the chromatographic lipophilicity (log kw), polarizability and topological polar surface area. The excellent statistics of the developed MLR equations (R2 > 0.8 for all columns) showed that it is possible to use the HPLC technique and retention data to produce reliable blood-brain barrier permeability models and to predict the log BB values of our pharmaceutically important molecules.

1 June 2010 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSKrzysztof Sztanke
Krzysztof Sztanke
WMWojciech Markowski
Wojciech Markowski
RŚRyszard Świeboda
Ryszard Świeboda
BPBeata Polak
Beata Polak

1 September 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KSKrzysztof Sztanke
Krzysztof Sztanke
Tomasz TuzimskiTomasz Tuzimski
Tomasz Tuzimski
MSMałgorzata Sztanke
Małgorzata Sztanke
JRJolanta Rzymowska
Jolanta Rzymowska
KPKazimierz Pasternak
Kazimierz Pasternak